XORTX Calls March 24, 2026 Shareholder Meeting to Vote on Share Consolidation and Governance Matters
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from XORTX Therapeutics Inc ( (TSE:XRTX) ).
XORTX Therapeutics Inc., a Calgary-based biopharmaceutical developer of kidney disease therapies listed on the TSX Venture Exchange and Nasdaq, has called its annual and special shareholders’ meeting for March 24, 2026. The meeting will review audited financial statements for 2024 and 2025, set the board size at five, elect directors, appoint the auditor, and seek shareholder approval of the company’s stock option plan.
Shareholders will also vote on a proposed consolidation of XORTX common shares at a ratio of up to five pre-consolidation shares for each post-consolidation share, as outlined in a management information circular dated February 25, 2026. The consolidation proposal, together with the governance and compensation items on the agenda, could reshape the company’s capital structure and board composition, potentially affecting its market profile and flexibility in future financing and strategic initiatives.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.46 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a Calgary-based biopharmaceutical company listed on the TSX Venture Exchange and Nasdaq under the symbol XRTX. The firm focuses on developing therapies, including those targeting xanthine oxidase pathways, for kidney disease and other indications with significant unmet medical needs in North American and global markets.
Average Trading Volume: 8,179
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$3.38M
For an in-depth examination of XRTX stock, go to TipRanks’ Overview page.
